Loading
PepGen Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest was filed 01 Oct 2025.
PepGen Inc.: what insiders have been doing
PepGen Inc. is a Health Care company. Its directors and officers file their transactions with SEC (Form 4). The last twelve months, up to 18 October 2026, brought 9 filings signed by 5 insiders.
The flow runs one way only: 3 sales worth €48k, from 3 insiders, and no purchase. McArthur James G filed the largest sale, €28k, on 6 March 2026.
For context, the typical company on the same exchange (median of 5,814 companies) published 19 filings over the same period, against 9 filings here. Since 2022, the database holds 9 purchases and 4 sales by insiders of the company.
The median gap between a trade and its publication by SEC (Form 4) is 1 day. For comparison, the SEC allows two business days to file a Form 4. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives.
Other companies in the same sector with recent insider buying flagged by our signals: Cooper Companies, Inc. and Anixa Biosciences Inc. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Insider Decl.
42
Thresholds
n/a
Buy Volume
€62M
9 ops. · all time
Sell Volume
€171,720
4 ops. · all time
Who traded when
BuySaleJames G. McArthur2 buys1 sale
Paul Streck1 buy1 sale
Noel Donnelly1 sale
Oxford Science Enterprises plc1 buy
RA Capital Management, L.P.1 buy
Since the insiders bought
- -55.1%Entry US$5.08 · Close at T+365 US$2.28
- -53.1%Entry US$4.71 · Close at T+365 US$2.21
- -7.2%Entry US$1.53 · Close at T+365 US$1.42
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate PepGen Inc. Strong Buy (bullish), based on 7 analysts. Average price target: US$11.29.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2025FY ended December 2025 · cache
US$2.85
Analyst consensus
7 analystsStrong buy
US$4.00Target US$11.29(+296%)US$20.00
Income statement
EBITDA-US$88.5M
Net income-US$89.7M0.0% margin
Valuation
PER (forward)-2.7x
P/Book1.5x
Beta1.89
Balance sheet & cash
Market capUS$197.4M
Total debtUS$17M
Free Cash Flow-US$81.9M
Debt / Equity12%
Profitability & ownership
ROE-68.4%
ROA-35.8%
% insiders0.2%
% institutions86.5%
Last declaration on 6 March 2026
Declarations42 total
2,032 shares@ US$6.23100.0% of flowCommon StockSEC:0001835597-26-000014:0
5,144 shares@ US$6.2318.9% of flowCommon StockSEC:0001835597-26-000012:0
1,832 shares@ US$6.2351.8% of flowCommon StockSEC:0001835597-26-000016:0
30,717 shares0Common StockSEC:0001835597-26-000010:0
34,557 shares0Common StockSEC:0001835597-26-000008:0
50,300 shares0Common StockSEC:0001835597-26-000006:0
76,793 shares0Common StockSEC:0001835597-26-000004:0
187,688 shares0Common StockSEC:0001835597-26-000002:0
35,000 shares0Common StockSEC:0001835597-25-000009:0
200,000 shares@ US$3.20100.0% of flowCommon StockSEC:0001856079-25-000003:0
Canonical exit: 29 Dec 2025 (T+90)
9,375,000 shares@ US$3.2050.5% of flowCommon StockSEC:0001231919-25-000265:0
Canonical exit: 25 Dec 2025 (T+90)
8,375 shares@ US$1.24148.2% of flowCommon StockSEC:0001127602-25-016227:0
Canonical exit: 28 Aug 2025 (T+90)
16,750 shares0Common StockSEC:0001127602-25-015213:0
10,000 shares@ US$1.3558.2% of flowCommon StockSEC:0001127602-25-012400:0
Canonical exit: 16 Jul 2025 (T+90)
41,500 shares@ US$1.1529.8% of flowCommon StockSEC:0001127602-25-011837:0
Canonical exit: 7 Jul 2025 (T+90)
13,400 shares0Common StockSEC:0001127602-25-008369:0
19,430 shares0Common StockSEC:0001127602-25-008365:0
60,719 shares0Common StockSEC:0001127602-25-008359:0
23,283 shares0Common StockSEC:0001127602-25-008366:0
3,200 shares0Common StockSEC:0001127602-25-006999:0
3,000 shares0Common StockSEC:0001127602-25-007006:0
201 shares@ US$10.210.6% of flowCommon StockSEC:0001127602-24-021044:0
12,625 shares@ US$10.2136.9% of flowCommon StockSEC:0001127602-24-020735:0
3,288 shares@ US$10.219.6% of flowCommon StockSEC:0001127602-24-020521:0
875 shares@ US$10.212.6% of flowCommon StockSEC:0001127602-24-019998:0
25 of 42 declarations
About PepGen Inc.
PepGen Inc. is a biopharmaceutical company focused on developing gene therapies for genetic diseases. It is listed on the XNAS market.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
